MB-105(March Biosciences)

N/A

Report date: 2025/11/13 10:06:48

Base Information

Drug NameMB-105(March Biosciences)
Drug Alias NameAutologus CD5 CAR T therapy(March Biosciences)MB-105(March Biosciences)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 modulatorsT lymphocyte replacements
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, T-CellLymphoma, Mantle-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMarch Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCancer Focus Fund LPMarch Biosciences Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLymphoma, Mantle-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A